Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Down 56.6% in July

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 83,800 shares, a decline of 56.6% from the June 30th total of 193,000 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 275,000 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on GANX shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a report on Thursday, July 11th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a report on Tuesday, April 23rd.

Gain Therapeutics Stock Up 1.0 %

Shares of Gain Therapeutics stock traded up $0.01 on Friday, reaching $1.05. 231,879 shares of the stock were exchanged, compared to its average volume of 284,731. The firm’s 50 day moving average is $1.66 and its 200-day moving average is $3.03. Gain Therapeutics has a one year low of $1.02 and a one year high of $5.33. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.77 and a current ratio of 2.77.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. On average, sell-side analysts forecast that Gain Therapeutics will post -1.03 EPS for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.